Insight Molecular Diagnostics (IMDX) Current Assets (2015 - 2026)

Insight Molecular Diagnostics has disclosed Current Assets across 12 years of filings, most recently posting $30.5 million for Q1 2026.

• Current Assets for Q1 2026 came in at $30.5 million, down 15.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.5 million (down 15.85% YoY), and the FY2025 annual result was $15.3 million, up 30.16% from the prior year.
• Current Assets came in at $30.5 million for Q1 2026 at Insight Molecular Diagnostics, up from $15.3 million in the prior quarter.
• In the past five years, Current Assets ranged from a high of $49.4 million in Q2 2022 to a low of $4.8 million in Q3 2024.
• The 5-year median for Current Assets is $21.0 million (2023), against an average of $21.4 million.
• Across the five-year window, Current Assets tumbled 71.67% in 2024 and soared 454.9% in 2025, its largest moves.
• Insight Molecular Diagnostics' Current Assets stood at $25.5 million in 2022, then slumped by 58.11% to $10.7 million in 2023, then increased by 9.92% to $11.8 million in 2024, then jumped by 30.16% to $15.3 million in 2025, then surged by 99.38% to $30.5 million in 2026.
• The last three Current Assets figures came in at $30.5 million (Q1 2026), $15.3 million (Q4 2025), and $21.4 million (Q3 2025), per Business Quant data.